| scholarly article | Q13442814 |
| P50 | author | David Oldach | Q42987314 |
| Patrick Marcellin | Q89798262 | ||
| Fabien Zoulim | Q33116701 | ||
| Thomas Berg | Q42981905 | ||
| P2093 | author name string | David Frederick | |
| Franck Rousseau | |||
| Katyna Borroto-Esoda | |||
| Fabien Lavocat | |||
| Huy Trinh | |||
| Jeff Sorbel | |||
| Sing Chan | |||
| Andrea Snow-Lampart | |||
| Emilio Suarez | |||
| Bernd Moller | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| tenofovir | Q155954 | ||
| emtricitabine | Q422604 | ||
| P304 | page(s) | 1207-1217 | |
| P577 | publication date | 2010-06-20 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection | |
| P478 | volume | 139 |
| Q37975548 | Adefovir dipivoxil in chronic hepatitis B: history and current uses |
| Q94544818 | Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes |
| Q35906015 | Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. |
| Q90416293 | Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review |
| Q37825909 | Antiviral drugs for HBV liver disease. |
| Q38210344 | Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China |
| Q34797281 | Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. |
| Q35844432 | Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B. |
| Q36779207 | Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B |
| Q36492635 | Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis |
| Q45891915 | Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective |
| Q35535861 | Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety |
| Q26851240 | Current and future directions for treating hepatitis B virus infection |
| Q40313106 | Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany |
| Q37250436 | Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France |
| Q28540372 | Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings |
| Q37564039 | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. |
| Q26765932 | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| Q36757579 | Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. |
| Q42151600 | Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. |
| Q40665887 | Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. |
| Q40967783 | Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. |
| Q46243261 | Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. |
| Q35846564 | Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy |
| Q42263082 | HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D. |
| Q34154952 | Hepatitis B Therapy in Pregnancy |
| Q39213627 | Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains |
| Q37855531 | Hepatitis B therapy |
| Q64966428 | Hepatitis B virus treatment: Management of antiviral drug resistance. |
| Q45353143 | Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. |
| Q54216584 | INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. |
| Q35992395 | Impact of partial reimbursement on hepatitis B antiviral utilization and adherence |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q38097858 | Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal |
| Q37696029 | Management of Antiviral Resistance in Chronic Hepatitis B. |
| Q37573939 | Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. |
| Q35838778 | Management of hepatitis B during pregnancy |
| Q35635637 | Management of hepatitis B in developing countries |
| Q37980893 | Management of treatment failure in chronic hepatitis B. |
| Q43493641 | Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis |
| Q38219020 | Molecular diagnosis and treatment of drug-resistant hepatitis B virus |
| Q45354171 | Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy |
| Q27030828 | Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B |
| Q35999165 | Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant |
| Q38071396 | Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. |
| Q37229851 | Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade |
| Q41148991 | Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. |
| Q35960972 | Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response |
| Q36018658 | Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir |
| Q35821198 | Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis |
| Q37825532 | Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? |
| Q37943006 | Review article: current antiviral therapy of chronic hepatitis B. |
| Q37634822 | SASLT practice guidelines for the management of hepatitis B virus. |
| Q37983258 | Selection of chronic hepatitis B therapy with high barrier to resistance |
| Q35594210 | Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. |
| Q44973263 | Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation |
| Q34847029 | Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis |
| Q37606550 | Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? |
| Q47598112 | Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance |
| Q40245246 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. |
| Q46044243 | Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. |
| Q42153085 | Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus. |
| Q42184918 | Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). |
| Q38038690 | Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. |
| Q35231822 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients |
| Q41175515 | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. |
| Q42159733 | Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures |
| Q47098116 | Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. |
| Q40940597 | Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir |
| Q42144275 | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance |
| Q44966178 | Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation |
| Q38520954 | The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists |
| Q37936321 | The management of chronic hepatitis B in Asian Americans |
| Q37581346 | Then and now: the progress in hepatitis B treatment over the past 20 years |
| Q58596648 | Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate |
| Q38259535 | Update on hepatitis B virus infection |
| Q42194740 | Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. |
Search more.